Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Having suffered considerable setbacks in launching its core pipeline drugs, Takeda Pharmaceutical will focus on expanding sales growth of existing products, including the gastronomic treatment Kapidex (dexlansoprazole) and gout medication Uloric (febuxostat) that were approved by U.S. FDA in early 2009, the company said in its earnings report and related documents May 11

You may also be interested in...



Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM

TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma

Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM

TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma

Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential

Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore

Latest News
See All
UsernamePublicRestriction

Register

SC071629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel